DKK1 and cancer: Meanwhile, the Wnt antagonist DKK1 (Dickkopf-1) has been implicated in the modulation of immune cell activities as well as the immunosuppressive microenvironment in cancers and has become a promising target for cancer immunotherapy (69, 70).